Aviir
The profile is currenly unclaimed by the seller. All information is provided by CB Insights.
Total Raised
$65.19MInvestors Count
7Deal Terms
6Aviir Funding, Aviir Valuation & Aviir Revenue
12 Fundings
Aviir's latest funding round was a Series D - III for $10M on June 21, 2013.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
6/21/2013 | Series D - III | $10M | 1 | |||
2/12/2013 | Series D - II | $10M | 5 | |||
9/19/2012 | Debt - II | $5M | 1 | |||
9/19/2012 | Line of Credit | |||||
12/20/2011 | Series D |
Date | 6/21/2013 | 2/12/2013 | 9/19/2012 | 9/19/2012 | 12/20/2011 |
|---|---|---|---|---|---|
Round | Series D - III | Series D - II | Debt - II | Line of Credit | Series D |
Amount | $10M | $10M | $5M | ||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 1 | 5 | 1 |
Aviir Deal Terms
6 Deal Terms
Aviir's deal structure is available for 6 funding rounds, including their Series D - III from June 21, 2013.
Round | Series D - III | Series D - II | Series D | Debt | Series C |
|---|---|---|---|---|---|
Funding Date | |||||
Pre-Money Valuation | |||||
Post-Money Valuation | |||||
Amount Raised | |||||
Shares Authorized | |||||
Issuance Price | |||||
Dividend Rate | |||||
Liquidation Preferences | |||||
Liquidation Price | |||||
Participation | |||||
Conversion Price | |||||
Anti Dilution | |||||
General Voting | |||||
Board Voting | |||||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series D - III | |||||||||||||||
Series D - II | |||||||||||||||
Series D | |||||||||||||||
Debt | |||||||||||||||
Series C |
Aviir Investors
7 Investors
Aviir has 7 investors. Bay City Capital invested in Aviir's Series D - III funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
3/12/2008 | 6/21/2013 | 7 Series B, Series C (2009), Series C - II (2009), Series C - III (2010), Series D (2011), Series D - II (2013), Series D - III (2013) | Venture Capital | California | ||
Venture Capital | New York | |||||
Venture Capital | California | |||||
Corporate Venture | Pennsylvania | |||||
First funding | 3/12/2008 | ||||
|---|---|---|---|---|---|
Last Funding | 6/21/2013 | ||||
Investor | |||||
Rounds | 7 Series B, Series C (2009), Series C - II (2009), Series C - III (2010), Series D (2011), Series D - II (2013), Series D - III (2013) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Corporate Venture | |
Location | California | New York | California | Pennsylvania |
You May Also Like
Genera Biosystems is a development phase company that designs, develops and produces and clinically effective human molecular diagnostics with a focus on women's health.
Helix Diagnostics LLC is pursuing development and commercialization of multiplexed DNA detection systems based on capillary electrophoresis.
MicroPhage's mission is to be a worldwide pioneer in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility/resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics.
Integrative Diagnostics is a early cancer detection company founded by Leroy Hood.
3PrimiR is researching how mutations in micro RNA molecules can be used in cancer diagnostics.
Columbia BioSystems Inc. is a company engaged in molecular Nano-diagnostics using Molecularly Imprinted Polymers (MIPs) for the rapid detection of pathogens such as Methicillin-resistant Staphylococcus aureus (MRSA) , Anthrax, HIV, and Trypanosomiasis (sleeping sickness). The company uses MIPs to bind to proteins and, upon binding, change color thereby signaling the presence of the bacteria, virus or parasite.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.